Clinical Trial: The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title:
Brief Summary: Under the modern precise radiotherapy technology, clear the best dose volume limit index and the limit value for the primary level prevention of heart injury; clear best follow-up interval and measures for heart function of breast cancer patients, to achieve the secondary prevention of cardiac injury; explore combined cardiovascular specialist optimal treatment strategy for heart injury in the treatment of breast cancer, during the tertiary prevention of cardiac injury; put forward rationalization proposal for prevention, treatment and follow-up for breast cancer associated with heart injury.
Detailed Summary:
Sponsor: Ruijin Hospital
Current Primary Outcome: event free survival [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- event free survival [ Time Frame: 5 years ]
- event free survival [ Time Frame: 10 years ]
- overall survival [ Time Frame: 5 years ]
- overall survival [ Time Frame: 10 years ]
- relative change of value of serum cardiac biomarker [ Time Frame: 1 year ]
- relative change of value of serum cardiac biomarker [ Time Frame: 5 years ]
- relative change of left ventricular ejection fraction (LVEF) [ Time Frame: 1 year ]
- relative change of LVEF [ Time Frame: 5 year ]
- relative change of LVEF [ Time Frame: 10 year ]
- score of life quality [ Time Frame: 1 year ]
- score of life quality [ Time Frame: 5 years ]
Original Secondary Outcome: Same as current
Information By: Ruijin Hospital
Dates:
Date Received: October 19, 2016
Date Started: November 2016
Date Completion:
Last Updated: October 21, 2016
Last Verified: October 2016